Efficacy of Sirolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in an Unselected Population With Coronary Artery Disease: 24-Month Outcomes of Patients in a Prospective Non-randomized Registry in Southern Turkey

Basit Öğe Kaydı
dc.authoridMuderrisoglu, Haldun/0000-0002-9635-6313
dc.authoridPekdemir, Hasan/0000-0002-4913-5120;
dc.authorwosidMuderrisoglu, Haldun/AAG-8233-2020
dc.authorwosidAltay, Hakan/AAE-1392-2021
dc.authorwosidPekdemir, Hasan/ABI-6096-2020
dc.authorwosidcicek, davran/AAC-8036-2020
dc.contributor.authorCicek, Davran
dc.contributor.authorPekdemir, Hasan
dc.contributor.authorKalay, Nihat
dc.contributor.authorBinici, Sueleyman
dc.contributor.authorAltay, Hakan
dc.contributor.authorMuderrisoglu, Haldun
dc.date.accessioned2024-08-04T20:32:31Z
dc.date.available2024-08-04T20:32:31Z
dc.date.issued2010
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: The efficacy of drug-eluting stents has been shown in randomized trials, but some controversy exists regarding which stent sirolimus-eluting or paclitaxel-eluting is more effective in unselected Turkish patients. Therefore, we investigated the clinical outcomes of patients who were treated with one type of these drug-eluting stents in the real world. Methods: We created a registry and prospectively analyzed data on a consecutive series of all patients who presented to our institution with symptomatic coronary artery disease between February 2005 and March 2007 and who were treated with the sirolimus- or the paclitaxel-eluting stent. The follow-up period after stent implantation was approximately 24 months. The primary end point was a major cardiac event, and the secondary end point was stent thrombosis. Informed consent was obtained from all subjects, and the study protocol was approved by the local ethical committee. Results: In total, 204 patients were treated with either the sirolimus-eluting stent (n = 103) or the paclitaxel-eluting stent (n = 101). The lesions in the 2 arms of the study were treated similarly by conventional technique. At 24-month follow-up, patients who received the paclitaxel-eluting stent showed significantly higher rates of non-Q-wave myocardial infarction (1.9% vs 5.9%; P: .002), target vessel revascularization (1.9% vs 4.9%; P: .002), coronary artery bypass graft surgery (1.9% vs 6.9%; P: .001), and late stent thrombosis (1.9% vs 3.9%, P: .002). Conclusions: Patients who received the sirolimus- eluting stent showed better clinical outcomes compared with those who had the paclitaxel-eluting-stent.en_US
dc.identifier.endpage196en_US
dc.identifier.issn1449-1907
dc.identifier.issue4en_US
dc.identifier.pmid20596361en_US
dc.identifier.scopus2-s2.0-77955527245en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage191en_US
dc.identifier.urihttps://hdl.handle.net/11616/95103
dc.identifier.volume7en_US
dc.identifier.wosWOS:000280469200003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherIvyspring Int Publen_US
dc.relation.ispartofInternational Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcoronary artery diseaseen_US
dc.subjectdrug-eluting stenten_US
dc.subjectmajor adverse cardiac eventen_US
dc.subjectstent thrombosisen_US
dc.titleEfficacy of Sirolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in an Unselected Population With Coronary Artery Disease: 24-Month Outcomes of Patients in a Prospective Non-randomized Registry in Southern Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu